<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03838406</url>
  </required_header>
  <id_info>
    <org_study_id>1771-001-287</org_study_id>
    <nct_id>NCT03838406</nct_id>
  </id_info>
  <brief_title>BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer</brief_title>
  <official_title>A Pilot Trial of Platinum Based Chemotherapy According to BRCA Expressions as First-line Chemotherapy in Patients With Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung-Ang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluated the incidence of BRCA loss in patients with advanced gastric&#xD;
      cancer and observed the treatment outcome and prognosis according to BRCA loss. And the&#xD;
      investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stomach cancer is still the leading cause of cancer deaths globally and is reported to be the&#xD;
      second leading cause of cancer deaths in Korea (18.7%). Although the number of radical&#xD;
      resection has increased due to the development of early diagnosis, many patients experience&#xD;
      recurrence after radical resection. It is also diagnosed as a non - resectable disease&#xD;
      locally advanced at the time of initial diagnosis, or with a metastasis. In patients with&#xD;
      recurrent / metastatic gastric cancer, conventional palliative chemotherapy is the best&#xD;
      treatment, and in advanced gastric cancer, combination therapy with fluoropyrimidine&#xD;
      (fluorouracil, capecitabine, S1) and platinum (oxaliplatin, cisplatin). The progression-free&#xD;
      survival was 3-5 months, and overall survival of 6-10 months in metastatic gastric cancer&#xD;
      patients.&#xD;
&#xD;
      The investigators evaluated the incidence of BRCA loss in patients with advanced gastric&#xD;
      cancer and observed the treatment outcome and prognosis according to BRCA loss. And the&#xD;
      investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the proportion of patients who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the time from diagnosis to death by any cause and progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the time from diagnosis to death by any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>BRCA Gene Rearrangement</condition>
  <arm_group>
    <arm_group_label>BRCA1 positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX or CAPOX Chemotherapy&#xD;
FOLFOX :&#xD;
Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.&#xD;
CAPOX:&#xD;
Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRCA1 negative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX or CAPOX Chemotherapy&#xD;
FOLFOX :&#xD;
Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.&#xD;
CAPOX:&#xD;
Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>BRCA 1</intervention_name>
    <description>The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.</description>
    <arm_group_label>BRCA1 negative</arm_group_label>
    <arm_group_label>BRCA1 positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>FOLFOX :&#xD;
Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.&#xD;
CAPOX:&#xD;
Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.</description>
    <arm_group_label>BRCA1 negative</arm_group_label>
    <arm_group_label>BRCA1 positive</arm_group_label>
    <other_name>FOLFOX or CAPOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic gastric cancer( Adenocarcinoma)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance 0-2&#xD;
&#xD;
          -  one more measure lesion&#xD;
&#xD;
          -  White blood cell count (WBC) &gt; 3000/ul , Platelet &gt; 75,000/ul&#xD;
&#xD;
          -  Normal kidney function (serum creatinine &lt; 1.5 ULN)&#xD;
&#xD;
          -  Normal Liver function (Aspartate aminotransferase (AST)/ Alanine aminotransferase&#xD;
             (ALT) &lt; 3 times of upper normal limit, if liver metastasis, AST/ALT &lt; 5 times of upper&#xD;
             normal limit)&#xD;
&#xD;
          -  life expectancy is more than 3 months&#xD;
&#xD;
          -  Conventional surgery that does not cause the transformation of the target lesion is&#xD;
             allowed&#xD;
&#xD;
          -  The patient who voluntarily decided to participate in this study and agreed in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Her-2 positive advanced gastric cancer&#xD;
&#xD;
          -  Central nervous system metastases requiring treatment with symptoms&#xD;
&#xD;
          -  Major uncontrolled cardiovascular disease (including myocardial infarction and&#xD;
             congestive heart failure within 6 months)&#xD;
&#xD;
          -  Uncontrolled infection or other serious diseases&#xD;
&#xD;
          -  Patients with serious medical conditions or serious illnesses&#xD;
&#xD;
          -  Patient who is pregnant or lactating&#xD;
&#xD;
          -  Adjuvant chemotherapy before 6 months (patients who have not received platinum-based&#xD;
             chemotherapy even if they are 6 months old can register)&#xD;
&#xD;
          -  In the past, if the primary lesion or target lesion was treated with radiation (if the&#xD;
             recurred lesion is outside the range of radiation therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Gyu Hwang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Ang University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung-Ang University</investigator_affiliation>
    <investigator_full_name>In Gyu Hwang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Capecitabine plus Oxalipatin (CAPOX)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

